Cargando…
Design aspects of COVID‐19 treatment trials: Improving probability and time of favorable events
As a reaction to the pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a multitude of clinical trials for the treatment of SARS‐CoV‐2 or the resulting corona disease 2019 (COVID‐19) are globally at various stages from planning to completion. Although some attempts were ma...
Autores principales: | Beyersmann, Jan, Friede, Tim, Schmoor, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653377/ https://www.ncbi.nlm.nih.gov/pubmed/34677829 http://dx.doi.org/10.1002/bimj.202000359 |
Ejemplares similares
-
Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017) -
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021) -
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks
por: Stegherr, Regina, et al.
Publicado: (2021) -
Improving outcomes of AF ablation by integrated personalized lifestyle interventions: rationale and design of the prevention to improve outcomes of PVI (POP) trial
por: Vermeer, Jasper, et al.
Publicado: (2023) -
Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
por: Becher, Marc Ulrich, et al.
Publicado: (2021)